文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

佐利氟达星对比头孢曲松联合阿奇霉素治疗无并发症泌尿生殖道淋病:一项国际、随机、对照、开放标签、3期、非劣效性临床试验

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.
PubMed 文献 · Lancet · 2025-12-11

这项国际3期非劣效性试验将930例无并发症泌尿生殖道淋病患者按2:1随机分配至单剂佐利氟达星3g口服组(n=621)或头孢曲松500mg肌注联合阿奇霉素1g口服组(n=309)。微生物学治愈率佐利氟达星组为90.9%(460/506),对照组为96.2%(229/238),估计差异5.3%(95%CI 1.4-8.6),置信区间上限低于12%非劣效界值。佐利氟达星非劣效于对照方案且安全性相似。

要点

  • 佐利氟达星组微生物学治愈率90.9%(95%CI 88.1-93.3),对照组96.2%(95%CI 92.9-98.3)。
  • 两组治愈率差异5.3%(95%CI 1.4-8.6),上限低于预设12%非劣效界值。
  • 佐利氟达星耐受性良好,两组不良事件相似,未报告严重不良事件。

核心结论

  • 佐利氟达星在治疗无并发症泌尿生殖道淋病方面非劣效于头孢曲松联合阿奇霉素,且安全性特征相似。
  • 这些数据提示佐利氟达星可能作为无并发症泌尿生殖道淋病的有效口服治疗选择。

研究设计与样本

  • 3期、多国、随机、对照、开放标签、非劣效性临床试验,在比利时、荷兰、南非、泰国和美国的17家门诊诊所开展。
  • 纳入年龄12岁及以上、临床怀疑无并发症泌尿生殖道淋病的参与者,按2:1随机分配至佐利氟达星3g单剂口服组(n=621)或头孢曲松500mg肌注联合阿奇霉素1g口服组(n=309)。
  • 主要终点为微生物学意向治疗(泌尿生殖道)人群在治愈检测(第6天±2天)时的微生物学治愈率(通过尿道或宫颈内膜培养确定淋病奈瑟菌根除)。
  • 若治疗差异(对照药减佐利氟达星)双侧95%CI上限低于12%非劣效界值,则判定为非劣效。

主要发现

  • 2019年11月6日至2023年3月16日筛查1011例患者,81例不符合筛查标准,930例被随机分配至佐利氟达星组(n=621)或对照组(n=309)。
  • 参与者平均年龄29.7岁(SD 9.4);930例中815例(88%)出生时指定为男性,115例(12%)出生时指定为女性;514例(55%)为黑人或非裔美国人,285例(31%)为亚洲人,113例(12%)为白人。
  • 治愈检测时微生物学意向治疗(泌尿生殖道)人群的微生物学治愈率:佐利氟达星组506例中460例(90.9%,95%CI 88.1-93.3),对照组238例中229例(96.2%,95%CI 92.9-98.3)。
  • 组间估计差异为5.3%(95%CI 1.4-8.6),置信区间上限在预设的12%非劣效界值内。
  • 佐利氟达星组最常见治疗中出现的不良事件包括头痛(619例中61例,10%)、中性粒细胞减少(42例,7%)和白细胞减少(24例,4%);对照组为注射部位疼痛(308例中38例,12%)、中性粒细胞减少(24例,8%)和腹泻(22例,7%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Development of new treatments for gonorrhoea is a global public health priority. We aimed to evaluate the efficacy and safety of zoliflodacin versus ceftriaxone plus azithromycin in patients with uncomplicated urogenital gonorrhoea. METHODS: In this phase 3, multinational, randomised, controlled, open-label, non-inferiority clinical trial, participants aged 12 years and older with clinical suspicion of uncomplicated urogenital gonorrhoea were eligible for inclusion. The trial was done in 17 outpatient clinics in Belgium, the Netherlands, South Africa, Thailand, and the USA. Participating countries with high disease prevalence were identified for participation in the study. Sites selected for participation were led by principal investigators with research experience, who were knowledgeable in HIV or sexually transmitted infections and treatment. Feasibility questionnaires and prestudy visits assessed sexually transmitted infection case management guidelines, clinical services, and resources (ie, facility, staff, proposed composition of the study team, standard sexually transmitted infection services offered at the site, assessment of laboratory capacity, research experience and ethical review of clinical trials). Eligible participants were randomly assigned (2:1) to receive a single dose of zoliflodacin 3 g (oral) or ceftriaxone 500 mg (intramuscular) plus azithromycin 1 g (oral). Treatment assignment was known to the participants and their treating clinicians; however, microbiology laboratory staff were masked and the sponsor's central study team were masked until after database lock. The primary endpoint was the proportion of patients with microbiological cure (eradication of Neisseria gonorrhoeae, determined by urethral or endocervical culture) at test of cure (TOC; day 6 ± 2) in the microbiological intention-to-treat population. The primary efficacy analysis declared non-inferiority if the upper bound of the two-sided 95% CI for the treatment difference (comparator minus zoliflodacin) fell below the 12% non-inferiority margin. The trial is registered with ClinicalTrials.gov, NCT03959527, and EudraCT, 2019-000990-22. FINDINGS: Between Nov 6, 2019, and March 16, 2023, 1011 patients were screened. 81 patients did not meet screening criteria and 930 participants were randomly assigned to zoliflodacin (n=621) or comparator (n=309). The mean participant age was 29·7 years (SD 9·4). 815 (88%) of 930 participants were assigned male at birth and 115 (12%) participants were assigned female at birth. 514 (55%) of 930 participants were Black or African American, 285 (31%) were Asian, and 113 (12%) were White. Microbiological cure rates at TOC in the microbiological intention-to-treat (urogenital) population (primary efficacy endpoint) were 460 (90·9%, 95% CI 88·1-93·3) of 506 participants for zoliflodacin and 229 (96·2%, 92·9-98·3) of 238 participants for comparator. The estimated difference between groups was 5·3% (95% CI 1·4-8·6) and the upper confidence interval limit was within the prespecified non-inferiority margin of less than 12%. Zoliflodacin was generally well tolerated and adverse events were similar between treatment groups. The most frequently reported treatment-emergent adverse events included headache (61 [10%] of 619 patients), neutropenia (42 [7%]), and leukopenia (24 [4%]) in the zoliflodacin group and injection site pain (38 [12%] of 308 patients), neutropenia (24 [8%]), and diarrhoea (22 [7%]) in the comparator group. The majority of adverse events were mild or moderate in severity. No serious adverse events were reported. INTERPRETATION: Zoliflodacin was non-inferior to ceftriaxone plus azithromycin for the treatment of uncomplicated urogenital gonorrhoea and had a similar safety profile. These data suggest a potential role for zoliflodacin as an effective oral treatment option for uncomplicated urogenital gonorrhoea. FUNDING: German Federal Ministry of Research, Technology and Space, UK Department of Health and Social Care as part of the Global Antimicrobial Resistance Innovation Fund, Japan Ministry of Health, Labour and Welfare, Netherlands Ministry of Health, Welfare and Sport and Directorate-General for International Cooperation, Switzerland Federal Office of Public Health, and the Canton of Geneva, Switzerland.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Luckey A, Balasegaram M, Barbee LA, et al. Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial. Lancet. 2025. PMID: 41391465. doi:10.1016/S0140-6736(25)01953-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。